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Background: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal
prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial.
Patients and methods: The R-CHOP 14 versus 21 trial compared R-CHOP administered two- versus three weekly in previously
untreated patients aged18 years with bulky stage I–IV DLBCL (n¼ 1080). Details of CNS prophylaxis were retrospectively collected
from participating sites. The incidence and risk factors for CNS relapse including application of the CNS-IPI were evaluated.
Results: 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate (MTX) n¼ 163, intravenous (IV) MTX n¼ 2,
prophylaxis type unknown n¼ 11 and IT MTX and cytarabine n¼ 1). At a median follow-up of 6.5 years, 21 cases of CNS relapse
(isolated n¼ 11, with systemic relapse n¼ 10) were observed, with a cumulative incidence of 1.9%. For patients selected to
receive prophylaxis, the incidence was 2.8%. Relapses predominantly involved the brain parenchyma (81.0%) and isolated
leptomeningeal involvement was rare (14.3%). Univariable analysis demonstrated the following risk factors for CNS relapse:
performance status 2, elevated lactate dehydrogenase, IPI,>1 extranodal site of disease and presence of a ‘high-risk’ extranodal
site. Due to the low number of events no factor remained significant in multivariate analysis. Application of the CNS-IPI revealed
a high-risk group (4-6 risk factors) with a 2- and 5-year incidence of CNS relapse of 5.2% and 6.8%, respectively.
Conclusion: Despite very limited use of IV MTX as prophylaxis, the incidence of CNS relapse following R-CHOP was very low
(1.9%) confirming the reduced incidence in the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence.
ClinicalTrials.gov: ISCRTN number 16017947 (R-CHOP14v21); EudraCT number 2004-002197-34.
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Introduction
CNS relapse is a devastating complication of diffuse large B-cell
lymphoma (DLBCL) associated with a median survival of
2–5 months [1]. The risk appears to be less in the rituximab era
[2, 3]; however, the data are conflicting, with a decreased incidence
in some [4–9] but not all reported series [10–13].
Chemoprophylaxis frequently with IT or IV MTX, is a long-
standing strategy aiming to reduce the risk of CNS recurrence in
DLBCL; however there is a risk of associated toxicity and limited
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evidence of efficacy. As the reported incidence of CNS relapse in
the rituximab era in the absence of prophylaxis is 5.4% [10] ad-
ministration is currently limited to high-risk patients.
Several risk factors for CNS recurrence have been reported
including involvement of various extranodal (EN) sites by lymph-
oma at baseline, involvement of>1 EN site of disease [alone or in
combination with a raised lactate dehydrogenase (LDH) level], as
well as a high-intermediate/high-risk International Prognostic
Index (IPI) score, which are well-summarised by McMillan et al.
[2]. In addition, several biomarkers including the activated B-cell
(ABC) subtype of DLBCL [14], dual expression of MYC and BCL-
2 by immunohistochemistry [14], or MYC or ‘double-hit’ re-
arrangement [15] are associated with increased risk.
Recently, the German High-Grade Non-Hodgkin Lymphoma
Study Group (DSHNHL) reported a six-factor prognostic model,
the CNS-IPI, incorporating the five IPI factors and presence or ab-
sence of kidney and/or adrenal gland involvement to determine
the risk of CNS relapse for patients with aggressive B-cell lymph-
oma. This model stratified patients into three risk groups for CNS
relapse at 2 years: low [0–1 factors: 0.6%; 95% confidence interval
(CI), 0% to 1.2%]; intermediate (2–3 factors: 3.4%; 95% CI, 2.2%
to 4.4%) and high risk (4–6 factors: 10.2%; 95% CI, 6.3% to
14.1%) and was subsequently validated in an independent
population-based cohort of R-CHOP-treated patients with
DLBCL from the British Columbia Cancer Agency (BCCA) [16].
Here, we report an analysis evaluating CNS relapse for patients
enrolled within the prospective randomised UK NCRI R-CHOP-
14 versus 21 trial, including an evaluation of the CNS-IPI within
this cohort and data regarding delivery of prophylaxis.
Patients and methods
The phase III randomised R-CHOP 14 versus 21 trial compared
R-CHOP administered 2-weekly versus 3-weekly in the first-line treat-
ment of DLBCL. A total of 1080 patients aged18 years with previously
untreated bulky stage I–IV DLBCL were enrolled at 119 centres across the
UK between March 2005 and November 2008. We previously reported
that the primary end point of superior overall survival (OS) of R-CHOP-
14 compared with R-CHOP-21 was not met, and that R-CHOP-14 was
not superior to R-CHOP-21 for progression-free survival, response rate
or safety [17]. Patients with primary mediastinal B-cell lymphoma
(PMBL) were not excluded from trial participation and we recently re-
ported our outcomes for this subgroup of patients [18].
In accordance with the study protocol administration of CNS prophylaxis
(12.5 mg IT MTX) with the first three cycles of treatment or according to local
guidelines) was at the discretion of the local investigator, but recommended
as per protocol for patients with involvement of bone marrow, peripheral
blood, nasal/paranasal sinuses, orbit and testis. Details of CNS prophylaxis
were retrospectively collected from participating sites using case report forms.
The study database was interrogated to identify all cases where the
CNS was documented as a site of relapse at initial disease progression. To
ensure that all cases were captured where progression was reported local
investigators were also contacted retrospectively to determine if the CNS
was a site of involvement. Where a case of CNS relapse was identified in-
vestigators were asked to specify the site(s) involved.
The primary end point of this analysis was to determine the incidence
of CNS relapse. Progression-free survival and OS were calculated from
the date of registration, censored at the date last seen, and analysed using
Kaplan–Meier method.
Univariable (UVA) and multivariable (MVA) Cox regression analyses
were performed to investigate the risk factors for CNS relapse. The v2 test
or Fisher’s exact test were used to compare the demographics between
the following groups: group 1 (disease-free, n¼ 795), group 2 (systemic
relapse, n¼ 264) versus group 3þ 4 (CNS relapse (n¼ 21: non-isolated
n¼ 10, isolated n¼ 11).
The following parameters were assessed: sex, age (60 ver-
sus>60 years), WHO performance status (PS) (<2 versus 2), stage (I/II
versus III/IV), bulky disease>10 cm (present versus absent), B symptoms
(present versus absent), elevated LDH (present versus absent), IPI (0, 1,
2, 3, 4, 5), >1 EN (present versus absent), presence of a ‘high-risk’ EN
(bone, bone marrow, breast, kidney, orbit, nasal/paranasal sinuses, epi-
dural space, peripheral blood and testis) (present versus absent), trial
arm (R-CHOP-14 versus R-CHOP-21), CNS prophylaxis (yes versus
no), cell-of-origin (COO) according to the Hans [19] algorithm (ger-
minal centre B-cell (GCB) versus non-GCB subtype), BCL 2 transloca-
tion by fluorescence in-situ hybridization (FISH) (present versus
absent), BCL 6 rearrangement by FISH (present versus absent), MYC re-
arrangement by FISH (present versus absent), ‘double-hit’ by FISH (pre-
sent versus absent), MIB1 (<90 versus90), MIB1 (<80 versus80),
COO determined by gene expression profiling (GEP) (GCB versus ABC
versus Type III/unclassified).
The CNS-IPI was then applied to our cohort to investigate the inci-
dence of CNS relapse according to CNS-IPI risk group.
Results
Key baseline characteristics for the entire trial cohort are shown
in Table 1.
Case report forms outlining CNS prophylaxis details adminis-
tered on study were returned in 984/1080 (91.1%) cases, with
data missing for 96 cases. A total of 177/984 patients (18.0%)
received CNS prophylaxis within the trial. The type of prophy-
laxis administered was IT MTX (163/177), IV MTX (2/177), IT
MTX and IT cytarabine (1/177) and prophylaxis-type unknown
(11/177). Table 2 shows the proportion of patients receiving CNS
prophylaxis by EN sites of involvement at baseline.
Twenty-three potential cases of CNS relapse were identified.
Of these, two were excluded following discussion with the local
investigator due to (i) presence of a spinal mass which did not
penetrate the dura mater and (ii) CNS relapse occurred subse-
quent to initial disease progression. At a median follow-up of
6.5 years, the number of confirmed cases of CNS relapse was 21/
1080 (1.9%), including one patient from the previously reported
PMBL cohort. Over half the events were isolated (n¼ 11), with
the remainder occurring in association with recurrence of sys-
temic disease (n¼ 10); and the majority (14/21) occurred in the
first-year following study registration. The incidence of CNS re-
lapse was 2.0% (16/807) if prophylaxis was not administered and
2.8% (5/177) for those who received prophylaxis, or 2.5% (4/
163) for patients who received IT MTX.
Baseline characteristics for patients with CNS relapse are
shown in Table 1 and supplementary Table S1, available at
Annals of Oncology online. Data on molecular subtyping
(Illumina DASL
VR
platform) were available for 4/21 patients clas-
sified as GCB n¼ 2, ABC n¼ 1 and type III/unclassifiable n¼ 1
subtypes accordingly. CNS relapse predominantly involved the
brain parenchyma (17/21, 81.0%), for 14/17 this was the only site
of CNS relapse, 2/17 had concurrent spinal cord involvement and
1/17 had concurrent leptomeningeal infiltration. Three patients
(3/21, 14.3%) had isolated leptomeningeal involvement and for 1
patient (1/21) CNS relapse was diagnosed on clinical grounds,
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following presentation with a facial nerve palsy and arm weakness
in association with increased protein in the cerebrospinal fluid.
The median time to progression for a CNS and systemic relapse
was 8.1 months (95% CI, 1.0–15.1), and 10.9 months (95% CI,
9.2–12.6), respectively. OS from study registration comparing
relapse-free versus systemic relapse versus CNS relapse patient
groups is shown in Figure 1. The median OS following a diagnosis
of CNS relapse was 3.5 months (95% CI, 0.1–6.9) and 7.7 months
(95% CI, 6.0–9.4) following a systemic relapse.
Significant risk factors for CNS relapse by UVA were WHO PS
2 (P¼ 0.001), elevated LDH (P¼ 0.042), IPI (P¼ 0.004),>1 EN
site of disease (P< 0.001) and presence of a ‘high-risk’ EN site
(P¼ 0.001) (supplementary Table S2, available at Annals of
Oncology online). No factor remained independently significant
in MVA based on these 21 cases.
Applying the CNS-IPI patients were categorised as low-
risk¼ 313/1080 (29.0%), intermediate-risk 563/1080 (52.1%)
and high-risk¼ 204/1080 (18.9%) accordingly. The proportion
receiving CNS prophylaxis was 15.3%, 14.4% and 31.4% in each
group, respectively. The number of CNS relapses by group were:
low-risk¼ 2, intermediate-risk¼ 8 and high-risk¼ 11, with a 2-
year (0%, 1.2%; 95% CI, 0.2% to 2.2% and 5.2%; 95% CI, 1.9%
to 8.5%) and 5-year (0.8%; 95% CI, 0% to 2.0%, 1.7%; 95% CI,
0.5% to 2.9% and 6.8%; 95% CI, 2.9% to 10.7%) incidence of
CNS relapse accordingly (Figure 2). Adjusting for CNS-IPI risk
group according to use of CNS prophylaxis did not demonstrate
a clinical benefit (hazard ratio¼ 1.12; 95% CI, 0.40–3.14;
P¼ 0.83) (supplementary Table S3, available at Annals of
Oncology online).
Discussion
At a median follow-up of 6.5 years, the cumulative incidence of
CNS relapse of 1.9% following R-CHOP was very low. The ma-
jority of relapses involved the brain parenchyma and isolated
leptomeningeal involvement was rare. Relapses in the CNS
tended to occur earlier than systemic relapse, and most (14/21)
occurred within the first year following registration. Consistent
with prior studies [1] the prognosis following CNS relapse in our
cohort was poor, with a median OS of 3.5 months. One patient
with CNS relapse was from the recently reported PMBL subgroup
analysis equating to an incidence of 2.0% (1/50) for this cohort,
consistent with published reports in the rituximab era [20].
Although several risk factors for CNS relapse were identified
on UVA, none remained independently significant in MVA due
to the low number of events. None of the biomarkers tested were
significant in UVA, but this must be interpreted in the context of
low numbers tested. Application of the CNS-IPI identified a
high-risk group with 2 and 5-year incidences of CNS relapse of
5.2% and 6.8% respectively, providing further validation for this
risk model. The incidence of CNS relapse for patients selected to
receive prophylaxis was 2.8% (2.5% for patients who received IT-
MTX) which might suggest some efficacy for this therapy; how-
ever when we evaluated the CNS-IPI adjusting for prophylaxis
use, no benefit could be demonstrated overall, although small
numbers in some individual groups limits interpretation. Five
patients who developed CNS recurrence (parenchymal n¼ 4, iso-
lated leptomeningeal n¼ 1) received IT MTX prophylaxis
Table 1. Key baseline characteristics for the R-CHOP 14 versus 21 trial
cohort (n5 1080) and for patients with CNS relapse (n5 21)
R-CHOP 14
versus
21 cohort
Patients
with CNS
relapse
N5 1080 N 5 21
Median age (range), years 61 (19–88) 59 (38–78)
Age 60 years 476 (44.1%) 11 (52.4%)
Age >60 years 604 (55.9%) 10 (47.6%)
Gender
Male 582 (53.9%) 11 (52.4%)
Female 498 (46.1%) 10 (47.6%)
Performance status
0 544 (50.4%) 9 (42.9%)
1 392 (36.3%) 4 (19.0%)
2 144 (13.3%) 8 (38.1%)
Stage
I (bulky) 79 (7.4%) 1 (4.8%)
II 323 (30.1%) 3 (14.3%)
III 317 (29.5%) 4 (19.0%)
IV 355 (33.1%) 13 (61.9%)
Bulky disease 533 (49.5%) 12 (57.1%)
B symptoms 489 (45.3%) 12 (57.1%)
Elevated LDH 701 (64.9%) 18 (85.7%)
>1 site of extranodal disease 296 (27.4%) 14 (66.7%)
IPI score
0 83 (7.7%) 1 (4.8%)
1 233 (21.6%) 1 (4.8%)
2 306 (28.3%) 3 (14.3%)
3 279 (25.8%) 6 (28.6%)
4 154 (14.3%) 9 (42.9%)
5 25 (2.3%) 1 (4.8%)
MYC-rearrangement (N ¼ 359) 36 (10.0%) 0 (0%)
Double-hit-rearrangement
(N ¼ 354)
16 (4.5%) 0 (0%)
Table 2. Administration of CNS prophylaxis and incidence of CNS relapse
according to sites of DLBCL involvement at baseline
Site of lymphoma
involvement
N (%) N (%) with N (%) with
CNS prophylaxis CNS relapse
Bone marrowa 101 (9.4) 42 (41.6) 6 (5.9)
Peripheral blooda 0 (0.0) NA NA
Nasal/paranasal sinusesa 6 (0.6) 6 (100) 1 (16.7)
Orbita 2 (0.2) 1 (50.0) 0 (0)
Testisa 14 (1.3) 10 (71.4) 0 (0)
Bone 63 (5.8) 29 (46.0) 3 (4.8)
Breast 17 (1.6) 5 (29.4) 2 (11.8)
Epidural space 0 (0.0) NA NA
Kidney and/or adrenal gland 69 (6.4) 19 (27.5) 4 (5.8)
aAdministration of CNS prophylaxis was at the local investigator’s discre-
tion but recommended if there was involvement of these sites at base-
line as per protocol.
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(supplementary Table S1, available at Annals of Oncology on-
line), highlighting the potential for treatment-failures with this
approach.
The strength of our analysis lies in the evaluation of an un-
selected cohort of DLBCL patients aged18 years who were uni-
formly R-CHOP-treated within in the setting of a large
multicentre prospective clinical trial. The long duration of
follow-up is an additional strength given the propensity for late-
onset recurrences. However, as a retrospective evaluation of a
prospective trial the analysis was not pre-planned and the study
was not designed or powered at the outset to evaluate this par-
ticular end point. The low number of CNS events also precluded
the identification of independent risk factors.
Evaluation of CNS relapse in DLBCL poses several challenges
for researchers due to its rarity. Comparison between studies is
also inherently difficult due to the heterogeneity of the popula-
tions reported in the literature, some of which are selected [4, 6,
10, 12, 13], or include patients with other aggressive B-cell
lymphoma histologies as well as DLBCL.[4, 16, 21] Variation in
prophylaxis use between cohorts further complicates data
interpretation.
The addition of rituximab to CHOP has consistently improved
outcomes for patients with previously untreated DLBCL, but the
impact on preventing CNS recurrence is more controversial [4–
13, 22]. On the whole, consensus opinion supports the view that
there has been a reduction in CNS relapse in the rituximab era
consequent to improved control of systemic disease [2, 3].
The pattern of CNS relapse in DLBCL also appears to have
evolved with rituximab, with relapses increasingly involving the
brain parenchyma rather than the leptomeninges [1, 7, 8], the lat-
ter being more prevalent previously [1]. A higher proportion of
CNS recurrences occurring in isolation are also reported for
rituximab-treated patients [4, 6] similarly attributed to improved
systemic disease control.
Although we also identified a high-risk CNS-IPI group, overall
we observed a lower incidence of CNS relapse across all risk
groups than that reported by Schmitz et al. [16] and the distinc-
tion between low and intermediate-risk was less clearly defined in
our analysis. This may be explained by differences between the
cohorts studied, for example patients evaluated by the BCCA
were older with a higher proportion of patients with increased PS
(>2) and IPI as anticipated with a population-based cohort, in
contrast to our trial population where patients with PS>2 were
excluded from participation which may have resulted in fewer
CNS events. Furthermore the indications for CNS prophylaxis
differed between studies, in the DSHNHL trials prophylaxis was
mandated for patients with involvement of bone marrow, testes
or involvement of lymph nodes of the head and neck in 5/8 of
these studies [16], while for the BCCA cohort prophylaxis was ad-
ministered only to patients with sinus involvement for the main
duration of the analysis.
Controversy surrounds CNS prophylaxis given the limited and
conflicting evidence-base, potential for associated toxicity, and
consequent demand placed on hospital services. In practice IT
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Figure 1. Overall survival from study registration.
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MTX is the most widely used prophylaxis, and while several stud-
ies support this approach [23, 24], not all have demonstrated
benefit [4, 11]. Concerns also exist regarding IT administration
in terms of preventing parenchymal relapses in particular [2, 6].
As systemic MTX is the mainstay of therapy for primary CNS
lymphoma (PCNSL) and given the reported efficacy as CNS
prophylaxis [25] many advocate this mode of administration. In
our analysis however only a minority of patients (n¼ 2) received
IV MTX but despite this, the risk of CNS recurrence was ex-
tremely low, even in patients deemed to be high-risk at the outset.
In conclusion, our findings demonstrate a reduction in CNS
relapse rates in the rituximab era. For patients selected to receive
prophylaxis, the incidence of CNS relapse was 2.8%, which might
suggest some benefit, possibly reflected by a low incidence of
leptomeningeal relapse (where the IT route of administration is
most likely to exert effect); although an exploratory analysis of
CNS-IPI group adjusted for prophylaxis use did not show an
overall risk reduction. The low number of CNS events we
observed overall also calls into question the additional benefit of
using IV MTX in this setting, given the potential for increased
toxicity. Ultimately, however, randomised clinical trials will be
required to determine the optimal approach in high-risk patients.
In the future incorporation of novel agents such as lenalidomide,
ibrutinib, and nivolumab, which are currently being evaluated in
combination with R-CHOP, may conceivably reduce CNS re-
lapse rates even further in DLBCL given the emerging data on
their efficacy in relapsed or refractory PCNSL in the recently
reported clinical studies NCT01956695, NCT02542514 and
NCT02857426, respectively.
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